3 Stocks Pulling The Health Care Sector Downward

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 12 points (0.1%) at 15,069 as of Wednesday, May 8, 2013, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,670 issues advancing vs. 1,254 declining with 121 unchanged.

The Health Care sector currently is unchanged today versus the S&P 500, which is up 0.2%. A company within the sector that fell today was Gilead ( GILD), up 1.47. Top gainers within the sector include Shire ( SHPG), up 2.6%, Grifols ( GRFS), up 2.5%, Sanofi ( SNY), up 2.2%, Medtronic ( MDT), up 0.8% and Celgene Corporation ( CELG), up 0.7%.

TheStreet Ratings group would like to highlight 3 stocks pushing the sector lower today:

3. Jazz Pharmaceuticals ( JAZZ) is one of the companies pushing the Health Care sector lower today. As of noon trading, Jazz Pharmaceuticals is down $5.91 (-9.9%) to $53.60 on heavy volume Thus far, 2.4 million shares of Jazz Pharmaceuticals exchanged hands as compared to its average daily volume of 646,000 shares. The stock has ranged in price between $53.29-$55.90 after having opened the day at $55.90 as compared to the previous trading day's close of $59.51.

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, engages in the identification, development, and commercialization of pharmaceutical products for various medical needs in the United States, Europe, and other countries. Jazz Pharmaceuticals has a market cap of $3.5 billion and is part of the drugs industry. The company has a P/E ratio of 13.7, below the S&P 500 P/E ratio of 17.7. Shares are up 11.7% year to date as of the close of trading on Tuesday.

TheStreet Ratings rates Jazz Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Jazz Pharmaceuticals Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you liked this article you might like

Acorda Shares Down on FDA's 'Refusal to File' Letter - Biotech Movers

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Medivation Founder Takes Helm at Axovant, Shares Spike

Trevena, Synergy Lead Biotech Movers

Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix